Therapeutics
Search By Attributes
Search Results
| Name | Synonyms | FDA Status | Company | Target Type | Therapy Type | Approved For |
|---|---|---|---|---|---|---|
| RO7105705 | MTAU9937A, RG6100 |
Alzheimer's Disease (Phase 2) | AC Immune SA, Genentech, Hoffmann-La Roche | Tau | Immunotherapy (passive) | |
| Zagotenemab | LY3303560 | Alzheimer's Disease (Phase 2) | Eli Lilly & Co. | Tau, Unknown | Immunotherapy (passive) | |
| AADvac-1 | Axon peptide 108 conjugated to KLH | Alzheimer's Disease (Phase 2), Progressive Nonfluent Aphasia (Phase 1) | Axon Neuroscience SE | Tau | Immunotherapy (active) | |
| BIIB092 | gosuranemab, BMS-986168, IPN007 |
Progressive Supranuclear Palsy (Phase 2), Alzheimer's Disease (Phase 2) | Biogen, Bristol-Myers Squibb | Tau | Immunotherapy (passive) | |
| C2N 8E12 | ABBV-8E12 | Progressive Supranuclear Palsy (Phase 2), Alzheimer's Disease (Phase 2) | AbbVie, C2N Diagnostics, LLC | Tau | Immunotherapy (passive) |